IXICO Presents New Huntington's Disease Research

29 October 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces the presentation of new research in Huntington’s Disease (HD) at the latest European Huntington’s Disease Network (EHDN) Clinical Research Congress 2026.

The research evaluated a novel method designed to reduce unwanted differences in HD patient brain volume measurement data collected using different MRI scanners, equipment and clinical sites. The findings highlighted the importance of validating imaging analysis methods and preserving clinically relevant information when analysing brain imaging data, rather than assuming that reducing measurement variabilities always improves the ability to accurately track disease progression.

The research was conducted using the Huntington’s Disease Imaging Harmonisation (HD-IH) consortium data set. IXICO is a founding member of the HD-IH, a collaboration with leading biopharmaceutical companies and the CHDI Foundation. Through its proprietary AI-powered IXI™ platform, IXICO has analysed more than 6,000 MRI scans from over 2,000 participants, generating valuable insights into HD disease progression and advancing the development and validation of imaging biomarkers.

A summary of the research is available IXICO’s website on the Scientific Publications page.

Robin Wolz, Chief Scientific Officer of IXICO, commented: “In Huntington’s clinical trials, researchers measure changes in brain structures to monitor disease progression. However, differences between MRI scanners and clinical sites can introduce variability into these measurements, potentially making it harder to detect genuine disease-related changes. Our findings demonstrate the importance of ensuring that imaging biomarkers reliably capture meaningful changes in disease progression. This research reinforces IXICO’s position in Huntington’s disease and our commitment to advancing the science that underpins more effective clinical trials and the development of new treatments for patients.”